Type 2 diabetes mellitus is a subclass of diabetes that is not insulin-responsive or dependent . It initially presents with insulin resistance and hyperinsulinemia, eventually progressing to glucose intolerance, hyperglycemia, and overt diabetes . While once thought to exclusively affect adults, this is no longer the case . Patients typically exhibit obesity but rarely develop ketosis .

Prevention & Lipids

Type 2 diabetes

Cardiometabolic care in type 2 diabetes: SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, and cardiovascular and kidney outcome trials.

Also called T2DM, T2D, type 2 diabetes mellitus, diabetes

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Type 2 diabetes mellitus is a subclass of diabetes that is not insulin-responsive or dependent.1

Diagnosis and risk stratification

In women with type 2 diabetes mellitus, procollagen type III N-terminal propeptide (P3NP) does not appear to improve the diagnosis of dual-energy X-ray absorptiometry-defined sarcopenia.1 When incorporated into a clinical model, P3NP did not yield a clinically significant improvement, and as a sole predictor, it showed poor discrimination.1 Additionally, arterial stiffness is an area of study in type 2 diabetes, with increased arterial stiffness defined as a brachial-ankle pulse wave velocity of 1800 cm/s or greater.2 Complications such as diabetic foot ulcers, amputations, and diabetic peripheral neuropathy are associated with increased mortality risks of 89%, 123%, and 37%, respectively.3

Treatment

In patients with type 2 diabetes and obesity, sustained weight loss of more than 10% improves diabetes control.1 Medications like orforglipron, an oral non-peptide GLP-1 receptor agonist, have shown significant reductions in HbA1c at doses of 12 mg or greater.2 For cardiovascular outcomes, combining GLP-1 receptor agonists and SGLT2 inhibitors has been studied; out of 9,462 participants in Harmony Outcomes, 575 (6.1%) were treated with SGLT2 inhibitors at baseline.3 Semaglutide has been evaluated for reducing heart failure events in groups with type 2 diabetes.4 Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease with severely elevated albuminuria and type 2 diabetes.5 In a trial evaluating finerenone, 7437 patients underwent randomization, with a primary outcome event occurring in 458 of 3686 patients over a median follow-up of 3.4 years.5 In patients undergoing cataract phacoemulsification, optimal perioperative treatment for diabetic macular edema remains an important challenge, with approaches including anti-VEGF therapy and intraoperative dexamethasone implantation.6

FDA actions

FDA approvals, label changes, device decisions and recalls on Type 2 diabetes from the last three months.

FDA generic approvalSep 22, 2026

FDA generic approval: Empagliflozin

The FDA has noted an original approval for a tablet formulation. However, specific details regarding the drug name and indication were not provided in the announcement.

EMPAGLIFLOZINempagliflozin

FDA

FDA approvalSep 17, 2026

FDA approval: Empagliflozin

The FDA has issued a drug approval for an original submission available in a solution formulation. Further details regarding the drug's name and indication were not specified in the release.

EMPAGLIFLOZINempagliflozin

FDA

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis